Sean Bohen just wrote the handbook on how to make a quick fortune in biotech
If you ask anyone in drug development about what motivates them — or even if you don’t — you’re going to get a regular double-barreled blast about patients and unmet medical needs if you’re covering this industry. Less discussed and just as important during a heady IPO boom is a shot at the overnight fortunes that are on offer in the middle of a pandemic.
Sean Bohen’s team at Olema just spelled it all out in an S-1 that can serve as a compactly written handbook on the subject — provided you know the background.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.